Repurposing of activating transcription factor 3 (ATF3) activator molecules with potential wound-healing effects
Injury. 2025 Apr 4;56(6):112314. doi: 10.1016/j.injury.2025.112314. Online ahead of print.
ABSTRACT
BACKGROUND: Wound healing is a complex and regulated process that involves the coordinated action of key signaling pathways. Activating transcription factor 3 (ATF3) is a stress-inducible protein that has recently emerged as a critical modulator of cellular responses to injury, including those involved in wound healing.
AIM: The aim of this study was to explore the repurposing of existing pharmacological agents to activate ATF3 and evaluate their potential to enhance wound healing factors.
METHODS: We selected three compounds: retin-A, furosemide, and acrivastine based on their ability to modulate ATF3 expression and assessed their effects on wound healing processes in primary cell cultures. We evaluated wound healing-related genes such as LL-37, HBD-2, HBD-3, and VEGFA by qPCR, and a wound healing scratch assay using keratinocytes was conducted to evaluate cell migration.
RESULTS: Interestingly, retin-A induced the expression of key wound healing-related genes, including HBD-2, HBD-3, LL-37, and VEGF. Also, retin-A was the only compound showing wound healing effects, while furosemide and acrivastine did not exhibit any noticeable activity.
CONCLUSION: Our research highlights the potential of retin-A as therapeutic agents to improve wound healing, particularly in chronic wound models.
PMID:40220516 | DOI:10.1016/j.injury.2025.112314